Video: Using Inhalers and Puffers in Asthma

Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update

Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?

September 29th 2023

Respiratory Tripledemic 2022-23: An Expert Recap

April 6th 2023

Daily Dose: Dupilumab Potent Against Uncontrolled COPD with Type 2 Inflammation

September 26th 2023

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

May 20th 2022

Long-COVID Rehabilitation Interventions Improve Symptoms but Research on Safety Still Needed

Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update

Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?

September 29th 2023

Respiratory Tripledemic 2022-23: An Expert Recap

April 6th 2023

Daily Dose: Dupilumab Potent Against Uncontrolled COPD with Type 2 Inflammation

September 26th 2023

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

May 20th 2022

Long-COVID Rehabilitation Interventions Improve Symptoms but Research on Safety Still Needed

Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update

Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?

Related Content

Daily Dose: "Night Owls" Less Healthy, at Higher Risk for T2D / image credit folders-stethoscope ©New Africa/AdobeStock

September 29th 2023

Respiratory Tripledemic 2022-23: An Expert Recap

Your daily dose of the clinical news you may have missed.

April 6th 2023

Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Daily Dose: Dupilumab Potent Against Uncontrolled COPD with Type 2 Inflammation

September 26th 2023

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Your daily dose of the clinical news you may have missed.

May 20th 2022

Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Long COVID Rehab Interventions Improve but Safety Research still needed image credit ©Nejron Photo/stock.adobe.com

Long-COVID Rehabilitation Interventions Improve Symptoms but Research on Safety Still Needed

Dupilumab Potent Against Uncontrolled COPD with T2 Inflammation: BOREAS Trial Update

Meta-analysis: Among persons with symptoms of long COVID, respiratory and exercise training were effective but pooled information on safety was "uncertain, imprecise."